Liminatus Pharma, Inc. (LIMN) Income Statement
LIMN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLIMN revenue and net income
LIMN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LIMN quarterly EPS vs estimates
Liminatus Pharma beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 12, 2026.
LIMN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research & development | $0 | $2.7M | $3.8M | $1.9M | $3.8M |
| Sales, general & admin | $3.0M | $645,000 | $1.1M | $856,000 | $197,000 |
| Total operating expenses | $3.0M | $2.9M | $2.6M | $2.7M | $2.5M |
| Operating income | −$3.0M | −$2.9M | −$2.6M | −$2.7M | −$2.5M |
| Interest income | $76,589 | $122,526 | $10,000 | $0 | — |
| Interest expense | $215,903 | $138,102 | $175,000 | $219,000 | — |
| Income before taxes | −$10.2M | −$2.9M | −$1.2M | −$2.9M | $4.4M |
| Income taxes | — | $18,841 | $33,987 | $539,823 | — |
| Net income | −$10.2M | −$2.9M | −$1.2M | −$2.9M | $4.4M |
| EBITDA | −$10.0M | −$2.7M | −$1.1M | −$2.7M | $4.4M |
| EPS (diluted) | −$15.04 | −$20.24 | −$4.00 | $0.12 | −$0.25 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $468 | $518 | — | $542 | — | — | — | — | — | — | — |
| Gross profit | −$468 | −$518 | — | −$542 | — | — | — | — | — | — | — |
| Research & development | $600,000 | $400,000 | $0 | $0 | $0 | $200 | $357,066 | $714,134 | $1.6M | $715,000 | — |
| Sales, general & admin | $778,908 | $700,898 | $884,211 | $701,170 | $264,220 | $167,000 | $186,081 | $195,084 | $96,000 | $47,000 | — |
| Total operating expenses | $1.4M | $1.1M | $884,211 | $701,170 | $255 | $522,788 | $1.0M | $642,082 | $1.7M | $642,699 | $676,321 |
| Operating income | −$1.4M | −$1.1M | −$884,211 | −$701,170 | −$255 | −$522,788 | −$1.0M | −$642,082 | −$1.7M | −$642,699 | −$676,321 |
| Interest income | $8,223 | $0 | $0 | $0 | $52,206 | $43,526 | $34,481 | — | $19,000 | $8,000 | — |
| Interest expense | $18,844 | $18,638 | $19,051 | $19,052 | $115,512 | $136,763 | $92,706 | $77,220 | $63,000 | $17,000 | — |
| Income before taxes | −$1.4M | −$1.1M | −$8.2M | −$1.8M | −$255 | −$865,263 | −$637,737 | −$530,074 | −$1.8M | −$472,995 | −$300,290 |
| Income taxes | — | — | — | — | — | $3,051 | $5,163 | $4,780 | — | $13,600 | $23,601 |
| Net income | −$1.4M | −$1.1M | −$8.2M | −$1.8M | −$255 | −$868,314 | −$642,900 | −$534,854 | −$1.8M | −$486,595 | −$323,891 |
| EBITDA | −$1.4M | −$1.1M | −$8.1M | −$1.8M | $115,257 | −$728,500 | −$637,737 | −$530,074 | −$1.7M | −$369,906 | −$300,290 |
| EPS (diluted) | −$0.03 | −$1.56 | −$15.09 | −$0.07 | −$0.12 | −$6.14 | −$4.48 | −$3.72 | −$5.90 | −$3.33 | −$1.99 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LIMN's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LIMN financial results
Liminatus Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $10.2 million. Diluted earnings per share came to −$15.04.
See the LIMN stock overview for the latest quote and news, or the LIMN chart for price history and technical indicators.
LIMN income statement FAQ
Does Liminatus Pharma have revenue?
Liminatus Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Liminatus Pharma profitable?
No. Liminatus Pharma reported a net loss of $10.2 million in fiscal 2025.
What are Liminatus Pharma's earnings per share?
Liminatus Pharma earned $-15.04 per diluted share in fiscal 2025, compared with $-20.24 a year earlier.
When will Liminatus Pharma report its next earnings?
Liminatus Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Liminatus Pharma's fiscal year end?
Liminatus Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.